[Clinical experiences with cefixime in the treatment of bacterial infections of the lower respiratory tract].
In a prospective, open clinical trial 21 patients suffering from lower respiratory tract infections were treated with the new oral cephalosporin cefixime. The antibiotic was given at a dosage of 200 mg b. i. d. for seven to eleven days. Seventeen of 18 evaluable patients were cured or distinctly improved at the end of therapy as well as two days after the end of treatment. Clinical results correlated well with the results of the lung function tests, especially with the significant decrease of resistance. At the end of therapy all initially isolated pathogens were eradicated. The tolerability of cefixime was good, only in two patients treated mild and transient side effects were noticed (1 x diarrhea, 1 x epigastric pain).
Kersten
W
W
Krankenhaus Bethanien, Moers, Germany.
Müsken
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy*; D001996:Bronchopneumonia / Q000188:drug therapy; D020682:Cefixime; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002954:Citrobacter / Q000187:drug effects / Q000302:isolation & purification; D004352:Drug Resistance, Microbial; D004361:Drug Tolerance; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy*; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy; D011446:Prospective Studies; D011512:Proteus Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D020682:Cefixime; D002439:Cefotaxime
Klinische Erfahrungen mit Cefixim in der Behandlung von bakteriellen Infektionen der unteren Atemwege.